| Disease Specific Interactions between Host Protein and DME (HOSPPI) |
| ICD Disease Classification Healthy |
| ICD-11: Healthy |
Click to Show/Hide the Full List of HOSPPI: 7 HOSPPI
|
| Oligomerization |
| Cytochrome b5 (CYB5A) |
Health |
Heterodimer |
| Uniprot ID |
|
| Interaction Name |
CYB5A-CYP2C19 heterodimerization |
[1], [2] |
| Studied Cell Lines |
DLPC vesicles |
| Description |
Cytochrome b5 (CYB5A) is reported to heterodimerize with the CYP2C19 protein, which leads to an altered activity of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between CYB5A and CYP2C19 can modulate the drug-metabolizing process of Mephenytoin 4-hydroxylase. |
| Cytochrome P450 2C9 (CYP2C9) |
Health |
Heterooligomer |
| Uniprot ID |
|
| Interaction Name |
CYP2C9-CYP2C19 heterooligomerization |
[3] |
| Studied Cell Lines |
Living cells |
| Affected Substrate(s): |
Methoxychlor and S-mephenytoin
|
| Description |
Cytochrome P450 2C9 (CYP2C9) is reported to heterooligomerize with the CYP2C19 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between CYP2C9 and CYP2C19 can inhibit the drug-metabolizing process of Mephenytoin 4-hydroxylase. |
| Cytochrome P450 2E1 (CYP2E1) |
Health |
Heterooligomer |
| Uniprot ID |
|
| Interaction Name |
CYP2E1-CYP2C19 heterooligomerization |
[4] |
| Studied Cell Lines |
Escherichia coli cell line |
| Affected Substrate(s): |
7-Ethoxy-4-cyanocoumarin
|
| Description |
Cytochrome P450 2E1 (CYP2E1) is reported to heterooligomerize with the CYP2C19 protein, which leads to an increased activity of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between CYP2E1 and CYP2C19 can facilitate the drug-metabolizing process of Mephenytoin 4-hydroxylase. |
| Mutated NADPH-CYP450 reductase (mPOR) |
Health |
Heterooligomer |
| Uniprot ID |
|
| Interaction Name |
mPOR-CYP2C19 heterooligomerization |
[7] |
| Studied Cell Lines |
Reconstituted liposomes |
| Affected Substrate(s): |
S-mephenytoin
Omeprazole
Propranolol
|
| Description |
Mutated NADPH-CYP450 reductase (mPOR) is reported to heterooligomerize with the CYP2C19 protein, which leads to a suppressed activity of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between mPOR and CYP2C19 can inhibit the drug-metabolizing process of Mephenytoin 4-hydroxylase. |
| NADPH-CYP450 reductase (POR) |
Health |
Heterooligomer |
| Uniprot ID |
|
| Interaction Name |
POR-CYP2C19 heterooligomerization |
[8] |
| Studied Cell Lines |
Transformed E. coli C41 (DE3) cell line |
| Affected Substrate(s): |
S-mephenytoin
Omeprazole
Propranolol
|
| Description |
NADPH-CYP450 reductase (POR) is reported to heterooligomerize with the CYP2C19 protein, which leads to activation of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between POR and CYP2C19 can activate the drug-metabolizing process of Mephenytoin 4-hydroxylase. |
| Transcription-factor regulation |
| Estrogen receptor (ESR1) |
Health |
Repression |
| Uniprot ID |
|
| Interaction Name |
ESR1-CYP2C19 interaction |
[5] |
| Studied Cell Lines |
Embryonic kidney 293 CYP2C19 cell line |
| Ensembl ID |
|
| Description |
Estrogen receptor (ESR1) is reported to repress the transcription of CYP2C19 gene, which leads to a decreased expression of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between ESR1 and CYP2C19 can repress the drug-metabolizing process of Mephenytoin 4-hydroxylase. |
| Non-coding RNA regulation |
| hsa-miR-29a-3p |
Health |
Suppression |
| miRBase ID |
|
| Interaction Name |
hsa-miR-29a-3p--CYP2C19 regulation |
[6] |
| Studied Cell Lines |
HEK293 cell line |
| Description |
hsa-miR-29a-3p is reported to suppress CYP2C19 mRNA translation by binding to the 3' untranslated region (3'UTR) of CYP2C19 mRNA, which leads to a decreased expression of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. |
| ICD Disease Classification 02 Neoplasms |
| ICD-11: 2A90 Mature T-cell lymphoma |
Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
|
| Histone modification |
| Histone deacetylases (HDACs) |
T-cell acute lymphoblastic leukemia |
Repression |
| Uniprot ID |
|
| Interaction Name |
HDACs-CYP2C19 interaction |
[9] |
| Studied Cell Lines |
T-ALL cell line |
| Description |
Histone deacetylases (HDACs) are reported to deacetylate the CYP2C19 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between HDACs and CYP2C19 can inhibit the drug-metabolizing process of Mephenytoin 4-hydroxylase. |
| ICD-11: 2C12 Liver cancer |
Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI
|
| DNA methylation |
| DNA methyltransferase (DNMT) |
Liver cancer |
Significant hypermethylation |
| Uniprot ID |
|
| Interaction Name |
DNMT-CYP2C19 interaction |
[10] |
| Studied Cell Lines |
Live tissue |
| Description |
DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP2C19 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Mephenytoin 4-hydroxylase. As a result, the interaction between DNMT and CYP2C19 can significantly affect the drug-metabolizing process of Mephenytoin 4-hydroxylase. |
|
|
|
|
|
|
